CASI Pharmaceuticals Plans IND Submission for CID-103 in Antibody-Mediated Rejection and Receives Non-Binding Offer to Acquire Its China Operations.

The U.S. FDA has granted approval to EPKINLY® (epcoritamab-bysp) for individuals with relapse or refractory (R/R) follicular lymphoma (FL).

Lyell Immunopharma Announces Phase 1 Results for ROR1-targeted CAR-T Candidate, LYL797, Showing Dose-dependent Efficacy Enhanced by Anti-exhaustion Technology.

Simcere Zaiming, announced that their new anti-EGFR antibody treatment, Enlituo®, has been officially approved for sale by the China National Medical Administration.

HUADONG MEDICINE Reports Encouraging Phase I Outcomes for New Oral GLP-1 Receptor Agonist HDM1002.

Star Therapeutics Unveils Clinical Findings on VGA039, an Injectable Therapy for Von Willebrand Disease (VWD).

Arrowhead Pharmaceuticals to Progress RNAi Therapy Plozasiran into Phase 3 CAPITAN Trial for Cardiovascular Results.

Werewolf Therapeutics Presents Early Safety and Effectiveness Results from Phase 1 Study of WTX-330 in Patients with Advanced Solid Tumors or Non-Hodgkin Lymphoma.

EZHARMIA® Receives Approval in Japan as the First Dual EZH1 and EZH2 Blocker for Peripheral T-Cell Lymphoma Therapy.

vTv Therapeutics Announces Enrollment of First Participant in CATT1 Key Study for Cadisegliatin in Type 1 Diabetes.

TiumBio Unveils Promising Initial Clinical Data for TU7710, Its Hemophilia Therapy Candidate, at ISTH 2024.

The Phase 3 FLOW study presented at the 84th ADA Scientific Sessions showed a 1 mg dose of Ozempic® (semaglutide) injection decreased the risk of kidney disease-related events.